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Abstract
Purpose After complaints of too many low-specificity
drug-drug interaction (DDI) alerts on QT prolongation,
the rules for QT alerting in the Dutch national drug
database were restricted in 2007 to obviously QT-
prolonging drugs. The aim of this virtual study was to
investigate whether this adjustment would improve the
identification of patients at risk of developing Torsades de
Pointes (TdP) due to QT-prolonging drug combinations in a
computerized physician order entry system (CPOE) and
whether these new rules should be implemented.
Methods During a half-year study period, inpatients with
overridden DDI alerts regarding QT prolongation and with
an electrocardiogram recorded before and within 1 month
of the alert override were included if they did not have a
ventricular pacemaker and did not use the low-risk
combination cotrimoxazole and tacrolimus. QT-interval
prolongation and the risk of developing TdP were calculated
for all patients and related to the number of patients for
whom a QT-alert would be generated in the new situation
with the restricted database.
Results Forty-nine patients (13%) met the inclusion criteria.
In this study population, knowledge base-adjustment would
reduce the number of alerts by 53%. However, the positive
predictive value of QT alerts would not change (31% before
and 30% after) and only 47% of the patients at risk of
developing TdP would be identified in CPOEs using the
adjusted knowledge base.
Conclusion The new rules for QT alerting would result in a
poorer identification of patients at risk of developing TdP
than the old rules. This is caused by the many non-drug-
related risk factors for QT prolongation not being incorpo-
rated in CPOE alert generation. The partial contribution of
all risk factors should be studied and used to create clinical
rules for QT alerting with an acceptable positive predictive
value.
Keywords Computerized physician order entry . Patient
safety . Alert override . Computer-assisted drug therapy .
Error management . QT prolongation
Introduction
Many computerized physician order entry systems
(CPOEs) generate drug safety alerts to remind physicians
of potentially unsafe situations. Drug safety alerts are
frequently overridden, for example because the alert is
not patient-tailored or because the disadvantages of the
situation do not outweigh the advantages. A high number
of low-specificity alerts may cause physicians to override
important alerts along with unimportant ones, thereby
decreasing safety [1].
In the Netherlands, all hospital CPOEs make use of the
national drug database, which is updated monthly. This ‘G
Standard’ contains safety information for all drugs licensed
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in the Netherlands [2]. The G Standard introduced drug-
drug interaction (DDI) alerting on QT prolongation in
March 2005. QT prolongation may predispose patients to
developing Torsades de Pointes (TdP) and to sudden
cardiac death. After many complaints about low-
specificity alerts in the CPOEs, several drugs were
excluded from QT-alert generation in May 2007 [3, 4]
without any outcome measurements.
The aim of this study was to compare the rules for QT
alerting to see whether the 2007 rules would identify
patients at risk of developing TdP better than the 2005 rules.
The following questions were to be answered:
1. In what percentage of patients at risk of developing
TdP due to a combination of two QT-prolonging drugs
is a QT-prolongation DDI alert generated (sensitivity)?
2. In what percentage of generated QT-prolongation DDI
alerts is the patient really at risk of developing clinically
significant QT prolongation (positive predictive value of
the QT alert)?
Background
Many cardiac and noncardiac drugs can prolong the QT
interval on the electrocardiogram (ECG), thereby increasing
the risk of serious ventricular arrhythmias (e.g., TdP) and
sudden cardiac death. TdP has a low incidence, and the
prolongation of the absolute QTc interval beyond 500 ms
and/or an increase of more than 60 ms are regarded as
leading to an increased risk of TdP [5–7].
Many risk factors may increase the risk of developing
TdP such as gender, age, cardiovascular disease, and
electrolyte disturbances; elderly females are especially at
risk. Many drugs increase this risk to different extents,
and higher doses and renal failure may add an additional
risk [5,7].
The Dutch national drug database, the G Standard, has
included DDI alerts on QT prolongation since March 2005
[8]. At first, drugs from lists D and E from De Ponti [9, 10]
generated this alert, as well as all class Ia and III
antiarrhythmics [4]. List D contained all drugs clinically
associated with TdP, and list E included drugs with clinical
evidence for TdP plus an official warning of causing TdP
[8–10]. In 2006 a discussion took place about the relevance
and urgency of this DDI. Some hospital pharmacists
concluded after studying the literature that many combi-
nations were of minor importance with no need for action
[8, 11], although hospital pharmacists responsible for the
DDI alerts in the G Standard disagreed [12–14].
Since May 2007 Dutch QT alerting has been based on the
system of the Arizona Center for Education and Research
on Therapeutics [15]. This system earlier consisted of four
drug classes with a different risk of causing TdP: class 1
drugs were known to cause TdP, class 2 drugs had a
probable risk, and class 4 were unlikely to cause TdP. Class
3 drugs were contraindicated in patients with (congenital)
long QT-syndrome [3]. At present, three categories exist:
drugs with a risk of causing TdP (formerly class 1),
drugs with a possible risk (formerly class 2) and drugs
with a conditional risk (including the former class 4
drugs) [15].
In May 2007, the G Standard limited DDI alerting for
QT prolongation to combinations of class 1 drugs and
terfenadine and adjusted the information content of the
alert text (Figs. 1 and 2). Furthermore it introduced
contraindication alerting for patients with a prolonged QT
interval taking single drugs from classes 1 and 2,
sympathicomimetic drugs or terfenadine. The new rules
for DDIs resulted in a reduction in the number of drugs
generating the QT alert (from 30 to 20) and were based on
expert opinions formulated after studying and discussing
the available literature. Outcome measurements were not
performed [3].
Both drugs may prolong the QTc-interval. 
 
Recommendation:  
Use of several QTc-prolonging drugs may result in a higher risk of serious arrhythmias. The risk 
should be considered per patient.  
 
Patient WITHOUT risk factors: the risk of ventricular arrythmias is low.  
Patient WITH risk factors: use of the combination is discouraged, or make an ECG before starting the 
medication. 
 
Risk factors for prolonged QTc-interval: 
Fig. 1 First part of the old alert
text
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Methods
Setting
The 1,237-bed Erasmus University Medical Center,
Rotterdam, the Netherlands, uses the CPOE Medicatie/
EVS (Leiden, the Netherlands) [16] on all wards except
ICUs. This CPOE system for prescribing medication
generates intrusive drug safety alerts for DDIs, overdoses,
and therapeutic duplications based on information held in
the G Standard database. Overridden drug safety alerts are
routinely logged for pharmacy review.
Study population
All overridden QT-prolongation DDI alerts generated in
Medicatie/EVS version 2.20 between 1 February 2006
and 31 July 2006 in the Erasmus MC-Center location
(a general hospital) were used for patient selection.
Outpatients, patients with ventricular pacemakers, trans-
planted patients treated with the low-risk combination of
tacrolimus with cotrimoxazole (class 2 and 4), patients
who were long-term users of QT-prolonging drugs with
unknown start dates or who were no longer using the
combination were excluded. The secondary inclusion
criterion was patients with ECGs available from before
and within 1 month of the QT-alert override.
Measures
For each patient included, the interacting drugs, risk factors
for TdP, and digital ECG recordings (12-lead resting ECGs
recorded with a Mortara electrocardiograph) were collected.
Risk factors for TdP were defined as female gender,
age>65 years, presence of cardiovascular disease (myocar-
dial infarction, heart failure, atrial fibrillation, hypertension,
cerebrovascular accident, peripheral vasculopathy), diabetes
mellitus (use of glucose-lowering drugs), renal failure
(glomerular filtration rate<50 ml/min), and potassium level
<3.5 mmol/l. Increased risk of TdP was defined as QTc
interval>500 ms or an increase in the QTc interval>60 ms
[6]. Sensitivity was calculated as true positives/(true
positives+false negatives). Positive predictive value was
calculated as true positives/(true positives+false positives).
Results
In the 6-month study period, DDI alerts on QT prolonga-
tion were overridden for 368 patients. Of these, 319
patients were excluded for different reasons (Table 1). The
most frequent reasons for exclusion were the use of
Table 1 Patient selection
Patient category Number
Patients with overridden drug safety alerts on QT
prolongation from 1 February – 31 July 2006
368
Patients excluded 319
Treated on an outpatient basis 35
Using tacrolimus and low-dose cotrimoxazole 124
Combination not used any more 22
Long-term use of combination (start date unknown) 7
Ventricular pacemaker 4
Other reasons 8
< 2 ECGs 119
Patients included 49
Both drugs may prolong the QTc-interval and may possibly result in serious arrhythmias; symptoms 
are sudden dizziness or syncope. In the last extremity resulting in sudden cardiac arrest. 
Recommendation:  
A concrete recommendation cannot be given because cut off points for the decision are difficult to 
define. Several risk factors can be deduced from co medication, for example diuretics (hypokalemia),
or digoxin or a renin-angiotensin-aldosterone-system inhibitor (heart failure). The risk should be 
weighted per patients. Essentially, the combination should be avoided (for example by replacing
domperidon by metoclopramide). If this is impossible, an ECG should be recorded. 
QTc-prolonging drugs are contraindicated in case of long QT-syndrome or acquired prolonged QT-
interval. Alerting for this can be arranged by the contraindication prolonged QT-interval. 
Risk factors for prolonged QT-interval: 
Fig. 2 First part of the new alert
text
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tacrolimus and low-dose cotrimoxazole in transplant recip-
ients (n=124, 34%), the unavailability of ECG recordings
before and after initiation of the drug combination (n=119,
32%), and the patient being treated on an outpatient basis
(n=35, 9.5%).
Forty-nine patients met the inclusion criteria; Table 2
presents the patient characteristics. The mean number of non-
drug-related risk factors was 2.7 (SD 1.1). All patients had at
least one non-drug-related risk factor for developing TdP.
Fifteen patients (31%) were considered at risk for
developing TdP; Table 3 shows their patient character-
istics. All at-risk patients used two QT-prolonging drugs,
ranging from high risk (class 1) to low risk (4). The
number of non-drug-related risk factors per patient ranged
from 1 to 5.
In the new database since May 2007, many frequently
encountered combinations of QT-prolonging drugs no
longer generate a DDI alert in the CPOE. The last
column of Table 3 shows whether combinations would
result in a QT alert in the new situation. For 8 of the 15
patients with increased risk of TdP in our study (53%),
no alert would be generated with the new rules because
the drugs are “not classified” or do belong to classes 2 or
4. Assuming the CPOE with the old “inclusive” drug
database identified all patients at risk of developing TdP,
the modified database would result in a sensitivity of
47%. Table 4 shows whether an alert would be generated
for patients at risk of developing TdP in the new
situation. Twenty-three rather than 49 alerts would be
generated (47%). The positive predictive value in the
study population was 31% (15/49) in the old situation
and would be about the same (30%, 7/23) if the CPOE
would make use of the modified database.
Table 2 Characteristics of patients meeting the inclusion criteria
(n=49)
Characteristic Number (%)
Female gender 20 (41%)
Cardiovascular disease 44 (90%)
Diabetes mellitus 17 (35%)
Renal failurea 19 (42%)
Age>65 years 29 (59%)
Potassium level<3.5 mmol/lb 3 (6.7%)
a Calculation based on all patients for whom an estimated glomerular
filtration rate was available (n=45)
b Calculation based on all patients with a measured potassium level (n=45)
Table 3 Subjects at risk of developing Torsades de Pointes (n=15)
Gender Age Cardiovascular
disease
Diabetes
mellitus
GFR
(ml/min)
K+ level
(mmol/l)
Risk
factors
Drug 1 Drug 2 QTc2
(ms)
ΔQTc
(ms)
New
alert
Female 75 + + 13 4.1 5 Haloperidola (1) Amiodaronea (1) 504 29 +
Female 71 + − 37 4.2 4 Indapamidea (2) Promethazinea (NC) 470 64 −
Male 68 + − 49 4.1 3 Amiodarone (1) Haloperidola (1) 487 100 +
Male 72 + − 48 3.9 3 Amiodarone (1) Ketanserina (NC) 537 83 −
Female 62 + − 7 4.2 3 Amiodarone (1) Tacrolimusa (2) 592 201 −
Female 53 + − 49 4.1 3 Haloperidola (1) Tacrolimusa (2) 530 62 −
Male 72 + − 48 3.9 3 Sotalol (1) Erythromycina (1) 501 32 +
Male 51 + + 33 4.4 3 Tacrolimusa (2) Mianserina (NC) 510 122 −
Female 81 + − 80 3.6 3 Domperidonea (1) Amitriptylinea (4) 438 75 −
Male 68 + − >90 4.4 2 Chlorpromazinea (1) Cisapridea (1) 490 64 +
Male 61 + − 26 4.1 2 Haloperidola (1) Sotalola (1) 478 84 +
Male 64 + + 77 4.7 2 Sotalol (1) Amiodaronea (1) 502 73 +
Male 64 + + 2b Chlorpromazinea (1) Ketanserina (NC) 467 91 −
Male 64 + − 59 4.0 1 Haloperidola (1) Amiodaronea (1) 560 141 +
Male 45 + − >90 4.2 1 Haloperidola (1) Tacrolimusa (2) 492 84 −
Patients are categorized according to number of non-drug-related risk factors
+ Present, -absent, GFR glomerular filtration rate in ml/min, QTc2 QTc interval after QTc-alert override, ΔQTc change in QTc interval between
ECGs before and after QTc alert
Numbers in parentheses indicatedrug class according to www.torsades.org; NC not classified on www.torsades.org
a QTc-prolonging drug started at time of QTc alert
b Number of risk factors might have been higher due to unknown values
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Discussion
The decreased number of drugs generating QT alerts
successfully lowers the alert numbers in our study
population from 49 to 23. However, it does not address
the specificity problem adequately, as the positive
predictive value does not change. Furthermore, the QT-
rule modification introduces a sensitivity problem as the
new system would miss 53% of the patients at increased
risk of developing TdP. Reduction of the QT-alert
overload by excluding several drugs from QT-alert
generation clearly has unintended and undesirable
consequences.
One question is whether these results can be extrapolated
to the entire inpatient population. Only inpatients with an
ECG before and within 1 month of QT-alert overriding
were included. Thirty-two percent of the patients with QT-
alert overrides were excluded because ECGs were not
available to calculate the QT interval, and these could have
been low-risk patients. However, the excluded patients had
a lower average number of non-drug-related risk factors:
2.0 (SD 1.2). The patients included had a higher average
number of 2.7 (SD 1.1), which could have led to an
overestimation of the proportion of patients considered to
be at risk.
None of the patients in our study had zero non-drug-
related risk factors, and it is likely that the risk factors for
developing TdP (e.g., cardiovascular disease) led to an
overestimation of the positive predictive value. Inclusion of
the entire inpatient population would have resulted in an
even lower positive predictive value.
Furthermore, patients using the combination tacroli-
mus and cotrimoxazole were excluded because this very
frequently used combination in transplanted patients in
the Erasmus MC was perceived not to result in TdP. It
can be questioned, however, whether this assumption is
correct [17]. If the combination really is a low-risk
combination not resulting in TdP, inclusion of these
patients would have resulted in a higher positive predic-
tive value.
How can these unintended consequences be understood?
QT prolongation is dependent on age, gender, co-morbidity,
serum potassium level, renal function, drug class, and drug
dose. Although age and gender of the patients are known in
our CPOE, these items were not used in QT-alert generation
and suppression. QT-alert generation in Medicatie/EVS was
and is only dependent on drug class and is not tailored to
at-risk patients, so accuracy remains low. Furthermore, the
drugs now excluded from QT-alert generation are known to
have a probable or unlikely risk of causing TdP when used
as single drugs, but the effects of combinations of these
drugs in patients with non-drug-related risk factors are
unknown.
Error management
How should the problem of these low-specificity alerts be
managed? Ideally, QT alerts would only be generated for
patients really at risk of developing TdP, and they would be
suppressed if the risk is low [18]. However, to calculate the
overall risk of developing TdP, the contributions of all risk
factors, including drug class and dose, should be known.
This information is not known, and therefore effective
filtering of QT alerts for at-risk patients is not feasible. Only
by prospectively collecting ECGs before and after the
initiation of combinations of two or more QT-prolonging
drugs will we be able to determine the true risk of
developing clinically relevant QT-prolongation. It is only
with this knowledge that QT alerts with both high
sensitivity and specificity (positive predictive value) can
be developed. An acceptable positive predictive value is
open to debate. Bates proposed an override rate of less than
40% for strongly action-oriented suggestions [19], but this
seems to have been chosen arbitrarily. If however this
recommendation were to be followed, the current positive
predictive value of DDI alerts on QT prolongation should
be doubled.
We recommend that ECGs should be performed before
and within 1 week of the QT override. If postponement of
this drug therapy were undesirable, a single ECG after the
QT override would also give useful information. This
recommendation to record an ECG should be presented as
a clear message during the order entry process. Both old
and new alert texts are rather long and complicated (Figs. 1
and 2), and it is easy to modify the messages. It would be
very helpful if ECGs could be ordered from the CPOE, but
this type of integration is largely absent in Dutch hospital
CPOEs.
The drug lists on www.torsades.org are regularly
updated in contrast to the De Ponti list [3, 15]. The lists
at first only included drugs that were on the market in the
United States. Fortunately, drugs that are not (and no
longer) available in the U.S. (terfenadine, domperidone) are
included now. For the Dutch situation it should be kept in
mind however that ketanserin, mianserin, and promethazine
are absent on www.torsades.org [3, 15].
Table 4 Numbers of patients at risk of developing Torsades de
Pointes for whom a QT-prolongation DDI alert is generated in the new
situation (database restricted to obviously QT-prolonging drugs)
Alert generated (n) No alert generated (n)
Patients at risk of TdP 7 (true positives) 8 (false negatives)
Patients not at
risk of TdP
16 (false positives) 18 (true negatives)
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Strengths and weaknesses
This study had several limitations. It focused on the risk of
TdP by analyzing QT prolongation. Although this relation-
ship is not clear cut, this is the best way to study the risk of
developing TdP, as TdP has a low incidence [5–7]. QT
intervals show high diurnal variability, may be subject to
reading errors, and are dependent on serum drug level [5–7,
20, 21]. The ECGs in this study were not recorded under
standardized conditions, and this might have resulted in less
accurate QT intervals. This study did not aim to identify
risk patients with a high certainty, but mainly focused on
the difference between old and new rules for QT-
prolongation alerts in a CPOE. It elucidated a problem
requiring a prospective study including ECGs recorded
under standardized conditions and taking into account drug
serum levels.
Due to QT-interval variability, it can be questioned
whether it is correct to use absolute QT intervals >500 ms
or QT prolongation >60 ms as the best identification of
patients at risk of TdP [20, 21]. We used both measures
according to the guidelines of the European Medicines
Agency and only used the categories with most marked
increases to reduce the effect of QT variability [6].
DDIs may have been generated by adding one QT-
prolonging drug to an existing therapy containing
another QT-prolonging drug, but may also have been
the result of two newly prescribed QT-prolonging drugs.
Twenty-five patients (51% of the patients included)
already used one QT-prolonging drug, resulting in a
smaller increase in QT interval and a higher probability
of exceeding the limit of 500 ms. This was another
reason to include both QT-interval measures to identify
patients at risk of TdP.
A weakness of this study is that the study population may
differ from the whole patient population. Selection may have
been biased because patients taking the combination
tacrolimus-cotrimoxazole (34%) and patients without two
ECGs (32%) and with a lower number of non-drug-related
risk factors were excluded. It is unlikely however that
inclusion of the tacrolimus-cotrimoxazole combination
would change our conclusions that the new rules are worse.
This combination does not result in alert generation with the
adjusted rules. If it were a low-risk combination, inclusion
would increase the positive predictive value, but the
sensitivity would remain low. If it were a high-risk
combination, inclusion would result in a decreased positive
predictive value and sensitivity. Both effects are unintended.
The modifications of the G Standard excluded 11 drugs
generating QT alerts and added 1 drug, arsenic trioxide.
This could have had an effect on the sensitivity and positive
predictive value, but this drug was not prescribed in our
CPOE in the study period.
A drawback of the CPOE used in this study is that only
overridden alerts are logged for pharmacy review. Alerts
resulting in order cancellation are not available, and
override reasons are not required. Disguised observation
in the Erasmus MC revealed an override rate of>90% for
DDIs, including QT-prolongation alerts (unpublished data).
Notwithstanding these limitations, this study clearly
showed the unintended effects on patient safety of a
proposed measure to reduce alert overload, making use of
patient data from normal clinical practice.
Conclusion
Reducing QT-alert overload by excluding drugs without
proven risk of causing TdP from alert generation would
result in a considerable reduction in alert numbers,
would not change the positive predictive value, and
would introduce a sensitivity problem. The high number
of non-drug-related risk factors that are not included in
QT-alert generation could explain these unintended
consequences. Further outcome measurements should
be performed to elucidate the contribution of the non-
drug-related risk factors to the overall risk. Ideally,
clinical rules incorporating all risk factors could then be
developed to generate QT alerts with an acceptable
positive predictive value.
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